Golf Tournament 2012

Annual Golf Tournament


The First Annual Sharon Leigh Cancer Organization Golf Tournament

Sharon with Kelli and Mike from Cedar-Sinai
Was an amazing success!
The fundraising effort was very successful and lots of fun was had by everyone. We can't wait until next year!

June 29, 2012 proved to be an incredibly successful fundraising event considering the fact that the tournament, held at Monarch Dunes, was a first time happening. The tournament, the committee, and sponsors were able to raise over $40,000. The purpose of the tournament is for awareness and research for early detection of Ovarian cancer.

This was our signature fundraiser benefiting Cedars Sinai ovarian research.
(Listen to Sharon discuss the golf tournament on the Dave Congalton Show by clicking here)



Photos from the golf tournament:

Booklet Cover



One of the Tables

What a Beautiful Day

Getting Started

Checking it Out

Riding in Style

Closest to the Hole

Having Fun

Great Form

A Few Moments to Chat

The Winners

Our souvenir cups

The Raffle

The Wine

The Drawing

(note: below is our letter about the tournament, if you missed it but would still like to donate to help fund early detection of ovarian cancer click the button to the left, or read below.) 

Dear Friend:
If you thought you could perhaps help some of the 70% of women (wives, sisters, daughters, granddaughters) currently diagnosed with ovarian cancer too late to be saved, would you do it?

Ovarian cancer is the deadliest of the gynecological cancers, causing more deaths in the U.S. each year than all other gynecological cancers combined. The five-year survival rate is over 90% and long-term prognosis is good for those women diagnosed with ovarian cancer in Stage 1.

But only 30% of women diagnosed are still in Stage 1. The Sharon Leigh Cancer Organization, Inc., a nonprofit, was created on the Central California Coast to raise research funds and spread the word about the importance of early detection for ovarian cancers.

Now you can help increase the chances that women will benefit from early detection and that research break-throughs for ovarian cancer will emerge. The Sharon Leigh Cancer Organization is establishing its first outreach effort and fundraiser. An estimated 25,000 Central Coast women will be educated about the benefits of early detection of ovarian cancer through promotion of the event. Net proceeds from the inaugural fundraiser will benefit Cedars-Sinai ovarian research. Cedars-Sinai is a national leader in research supporting early detection of women’s cancers.

The First Annual “Ovarian Cancer Benefit Golf Tournament”, hosted by the Sharon Leigh Cancer Organization, will take place Friday, June 29, 2012, at the Monarch Dunes Golf Course. We ask that you consider helping us increase the number of women diagnosed with ovarian cancer in time for effective treatment. Please consider a donation to the Sharon Leigh Cancer Organization or a sponsorship for the First Annual Ovarian Cancer Benefit Golf Tournament.

Sharon Rude, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
(805) 473-8980

Monday, March 30, 2015
English Facebook Spanish Facebook Group English Facebook Group Twitter Ovarian Cancer Google+

Want to stay informed?

Up-to-date info on Ovarian Cancer

Like our Facebook page. Everyday we post the most recent breakthroughs and human interest stories on Ovarian Cancer.

Latest News

Information about ovarian cancer symptoms and treatments. Explore the latest medical research on ovarian cysts and ovarian cancer including including stages of the disease and new treatment options.
  • Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman’s tumor and extend the time period between initial treatment and the cancer’s return.
  • Overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.
  • A biomarker that will help lead to better predictions of the success of chemotherapy in ovarian cancer patients has been discovered by researchers. This discovery could lead to better treatment options in the fight against ovarian cancer, they say.
  • Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. In 2015, it is estimated that more than 21,000 new diagnoses and more than 14,000 deaths from this neoplasm will occur in the United States; less than 40 percent of women with ovarian cancer are cured.
  • Breast cancer patients who are given the hormone-blocking drug goserelin during chemotherapy are less likely to experience ovarian failure and more likely to have successful pregnancies, according to results from a recent study.
  • A surgical algorithm developed and implemented by ovarian cancer specialists dramatically increases the frequency of complete removal of all visible tumor – a milestone strongly tied to improved survival. The algorithm is a framework for a personalized surgical approach that allows surgeons to be "much smarter about whom we operate on up front, providing a more individualized approach to surgery that's led to better results for our patients," said one clinician.
  • The most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a new study. Serous ovarian cancers containing a variety of genetically-different cells were more likely to become resistant to treatment and come back again than cancers made of more similar cells. Women with this type of tumor also died sooner than those with less varied tumors.
  • Ovarian cancer is the deadliest of all cancers affecting the female reproductive system with very few effective treatments available. Prognosis is even worse among patients with certain subtypes of the disease. Now, researchers have identified a new therapeutic target in a particularly aggressive form of ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease.
  • Cancer researchers have identified a molecule they say is important to survival of anaplastic thyroid carcinoma (ATC) — a lethal tumor with no effective therapies. The molecule also seems to play a role in a wide range of cancers, they report.